 Emmaus Life Sciences Inc OTCQX:EMMA has announced real-world data on the companys prescription-grade L-glutamine oral powder, Endari, in preventing acute complications from sickle cell disease and hemolysis in pediatric and adult patients in French Guiana and Qatar. The data was introduced by the studys chief investigator Dr Mohamed Yassin and his co-authors at the 62nd Annual Meeting of the British Society for Haematology, held earlier in April. 